Translational neuroimaging of the CNS: Novel pathways to drug development

Molecular Interventions

Volumn 9, Issue 6, 2009, Pages 302-313

  Fox, Gerard B ^a   Chin, Chih Liang ^a   Luo, Feng ^a   Day, Mark ^a   Cox, Bryan F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; RADIOISOTOPE;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION TENSOR IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HUMAN; NEUROIMAGING; NEUROSCIENCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 75749128304     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.6.6     Document Type: Review

References (91)

1. Andersen, L.F., Meinert, L., Rygaard, C., Junge, J., Prento, P., and Ottesen, B.S. Thermal balloon endometrial ablation: Safety aspects evaluated by serosal temperature, light microscopy and electron microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 79, 63-68 (1998).
2. Chin, C.L., Fox, G.B., Hradil, V.P., Osinski, M.A., McGaraughty, S.P., Skoubis, P.D., Cox, B.F., and Luo, Y. Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis. Neuroimage 33, 1152-1160 (2006). This report presents a novel approach of assessing brain circuitry involved in drug-induced vomiting in awake animals via pharmacological MRI, which could translate into clinical trials for evaluating side effects.
3. Wang, Y.X. and Yan, S.X. Biomedical imaging in the safety evaluation of new drugs. Lab Anim. 42, 433-441 (2008).
4. Donnan, G.A. and Davis, S.M. Neuroimaging, The ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol. 1, 417-425 (2002).
5. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther. 83, 349-353 (2008).
6. Silva, A.C. and Bock, N.A. Manganese-enhanced MRI: an exceptional tool in translational neuroimaging. Schizophr. Bull. 34, 595-604 (2008).
7. Stephenson, D.T. and Arneric, S.P. Neuroimaging of pain: advances and future prospects. J. Pain 9, 567-579 (2008).
8. Wise, R.G. and Tracey, I. The role of fMRI in drug discovery. J Magn Reson Imaging. 23, 862-876 (2006).
9. Chin, C.L., Pauly, J.R., Surber, B.W., Skoubis, P.D., McGaraughty, S. Hradil, V.P., Luo, Y., Cox, B.F., and Fox, G.B. Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors. Synapse 62, 159-168 (2008). This work demonstrates the utility of using pharmacological MRI in awake animals to characterize selective drug actions.
10. Hoffman, J.M., Guze, B.H., Baxter, L.R., Mazziotta, J.C., and Phelps, M.E. [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies. Eur Neurol. 29 Suppl 3, 16-24 (1989).
11. Fukuda, A., Tanaka, M., Yamada, Y., Muramatsu, K., Shimano, Y., and Nishino, H. Simultaneous optical imaging of intracellular Cl- in neurons in different layers of rat neocortical slices: Advantages and limitations. Neurosci. Res. 32, 363-371 (1998).
12. Hoshi, Y. Functional near-infrared optical imaging: utility and limitations in human brain mapping. Psychophysiology 40, 511-520 (2003).
13. Licha, K. and Olbrich, C. Optical imaging in drug discovery and diagnostic applications. Adv. Drug Deliv. Rev. 57, 1087-1108 (2005).
14. Zhang, G.J., Chen, T.B., Hargreaves, R., Sur, C., and Williams, D.L., Jr. Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways. Na.t Protoc. 3, 891-899 (2008).
15. Fox, N.C., Black, R.S., Gilman, S., Rossor, M.N., Griffith, S.G., Jenkins, L., and Koller, M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572 (2005).
16. Jack, C.R., Jr., Slomkowski, M., Gracon, S. et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60, 253-260 (2003).
17. Korf, E.S., Wahlund, L.O., Visser, P.J., and Scheltens, P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 63, 94-100 (2004).
18. Ridha, B.H., Barnes, J., Bartlett, J.W., Godbolt, A., Pepple, T., Rossor, M.N., and Fox, N.C. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 5, 828-834 (2006).
19. Luo, F., Seifert, T.R., Edalji, R., Loebbert, R.W., Hradil, V.P., Harlan, J., Schmidt, M., Nimmrich, V., Cox, B.F., and Fox, G.B. Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 155, 263-269 (2008). This work presents the feasibility of characterizing pathogenic Aβ1-40-induced vascular dysfunction in mice via functional MRI, which highlights the possibility of applying this technique to the preclinical screening of novel drugs or antibodies targeting Alzheimer's disease modification.
20. Chin, C.L., Pai, M., Bousquet, P.F. et al. Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways. J. Neuroimmunol. 211, 49-55 (2009).
21. Chin, C.L., Tovcimak, A.E., Hradil, V.P. et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br. J. Pharmacol. 153, 367-379 (2008). This report provides the first clear evidence for quantifying in vivo functional selectivity between CB1 and CB2 receptors using pharmacological MRI.
22. Luo, F., Li, Z., Treistman, S.N., Kim, Y.R., King, J.A., Fox, G.B., and Ferris, C.F. Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge. J. Magn. Reson. Imaging. 26, 557-563 (2007). This report highlights the importance of testing compounds in awake animals during pharmacological MRI, since anesthesia may confound testing compound response.
23. Luo, F., Schmidt, K.F., Fox, G.B., and Ferris, C.F. Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment. J. Psychiatr. Res. 43, 1018-1024 (2009). This work highlights our improved understanding of the complex neuronal and vascular mechanisms of drug action via multi-modal imaging approaches.
24. Luo, Y., Hradil, V.P., Frost, D.J., Rosenberg, S.H., Gordon, G.B., Morgan, S.J., Gagne, G.D., Cox, B.F., Tahir, S.K., and Fox, G.B. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs 20, 483-492 (2009).
25. Yao, B.B., Hsieh, G., Daza, A.V. et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl- cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3Hthiazol-( 2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 328, 141-151 (2009). This work presents a reallife example of pharmacological MRI for novel CNS drug discovery.
26. Fox, N.C., Warrington, E.K., Freeborough, P.A., Hartikainen, P., Kennedy, A.M., Stevens, J.M., and Rossor, M.N. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 (Pt 6), 2001-2007 (1996).
27. Jack, C.R., Jr., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, E.G., and Kokmen, E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55, 484-489 (2000).
28. McEvoy, L.K., Fennema-Notestine, C., Roddey, J.C., Hagler, D.J., Jr., Holland, D., Karow, D.S., Pung, C.J., Brewer, J.B., and Dale, A.M. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251, 195-205 (2009).
29. Savoiardo, M. and Grisoli, M. Imaging dementias. Eur Radiol. 11, 484-492 (2001).
30. Schroder, J., Pantel, J., Schonknecht, P., and Essig, M. [Magnetic resonance imaging in clinical diagnosis of dementia]. Radiologe 43, 513-520 (2003).
31. Spires, T.L. and Hyman, B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx. 2, 423-437 (2005).
32. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
33. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., and Van der Linden, A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53, 607-613 (2005).
34. Jack, C.R., Jr., Wengenack, T.M., Reyes, D.A. et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 25, 10041-10048 (2005).
35. Jack, C.R., Jr., Marjanska, M., Wengenack, T.M., Reyes, D.A., Curran, G.L., Lin, J., Preboske, G.M., Poduslo, J.F., and Garwood, M. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist 13, 38-48 (2007).
36. Lee, J.H., Silva, A.C., Merkle, H., and Koretsky, A.P. Manganese-enhanced magnetic resonance imaging of mouse brain after systemic administration of MnCl2: dose-dependent and temporal evolution of T1 contrast. Magn. Reson. Med. 53, 640-648 (2005).
37. Delatour, B. and Dhenain, M. [Diagnosis of Alzheimer's disease: the contribution of preclinical research]. Bull. Acad. Natl. Med. 192, 345-360; discussion 360-341 (2008).
38. Basser, P.J. Inferring microstructural features and the physiological state of tissues from diffusion-weighted images. NMR Biomed. 8, 333-344 (1995).
39. Mori, S. and Zhang, J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 51, 527-539 (2006).
40. Ciccarelli, O., Catani, M., Johansen-Berg, H., Clark, C., and Thompson, A. Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol. 7, 715-727 (2008).
41. Sullivan, E.V. and Pfefferbaum, A. Diffusion tensor imaging and aging. Neurosci Biobehav Rev. 30, 749-761 (2006).
42. Kanaan, R.A., Kim, J.S., Kaufmann, W.E., Pearlson, G.D., Barker, G.J., and McGuire, P.K. Diffusion tensor imaging in schizophrenia. Biol. Psychiatry 58, 921-929 (2005).
43. Kubicki, M., McCarley, R., Westin, C.F., Park, H.J., Maier, S., Kikinis, R., Jolesz, F.A., and Shenton, M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 41, 15-30 (2007).
44. Hanyu, H., Sakurai, H., Iwamoto, T., Takasaki, M., Shindo, H., and Abe, K. Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. J. Neurol. Sci. 156, 195-200 (1998).
45. Firbank, M.J., Blamire, A.M., Krishnan, M.S., Teodorczuk, A., English, P., Gholkar, A., Harrison, R.M., and O'Brien, J.T. Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. Psychiatry Res. 155, 135-145 (2007).
46. Harms, M.P., Kotyk, J.J., and Merchant, K.M. Evaluation of white matter integrity in ex vivo brains of amyloid plaque-bearing APPsw transgenic mice using magnetic resonance diffusion tensor imaging. Exp. Neurol. 199, 408-415 (2006).
47. Song, S.K., Kim, J.H., Lin, S.J., Brendza, R.P., and Holtzman, D.M. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis. 15, 640-647 (2004).
48. Petrella, J.R., Coleman, R.E., and Doraiswamy, P.M. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226, 315-336 (2003).
49. Sperling, R. Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann. NY Acad. Sci. 1097, 146-155 (2007).
50. Lahti, K.M., Ferris, C.F., Li, F., Sotak, C.H., and King, J.A. Imaging brain activity in conscious animals using functional MRI. J. Neurosci. Methods 82, 75-83 (1998).
51. Chen, Y.C., Galpern, W.R., Brownell, A.L. et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med 38, 389-398 (1997).
52. Mueggler, T., Baumann, D., Rausch, M., and Rudin, M. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging. Magn. Reson. Med. 46, 292-298 (2001).
53. Schwarz, A., Gozzi, A., Reese, T., Bertani, S., Crestan, V., Hagan, J., Heidbreder, C., and Bifone, A. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 54, 1-10 (2004).
54. Bassett, S.S., Yousem, D.M., Cristinzio, C., Kusevic, I., Yassa, M.A., Caffo, B.S., and Zeger, S.L. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 129, 1229-1239 (2006).
55. Bookheimer, S.Y., Strojwas, M.H., Cohen, M.S., Saunders, A.M., Pericak-Vance, M.A., Mazziotta, J.C., and Small, G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343, 450-456 (2000).
56. Golby, A., Silverberg, G., Race, E., Gabrieli, S., O'Shea, J., Knierim, K., Stebbins, G., and Gabrieli, J. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain 128, 773-787 (2005).
57. Burggren, A.C., Small, G.W., Sabb, F.W., and Bookheimer, S.Y. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 44-51 (2002).
58. Sperling, R.A., Bates, J.F., Chua, E.F., Cocchiarella, A.J., Rentz, D.M., Rosen, B.R., Schacter, D.L., and Albert, M.S. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 44-50 (2003).
59. Mueggler, T., Baumann, D., Rausch, M., Staufenbiel, M., and Rudin, M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 23, 8231-8236 (2003).
60. Phelps, M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. USA 97, 9226-9233 (2000).
61. Hawkins, R.A. Brain energy metabolism and function during hepatic encephalopathy. Eur. J. Clin. Invest. 14, 313-314 (1984).
62. Kuschinsky, W. Coupling of blood flow and metabolism in the brain. J. Basic Clin. Physiol. Pharmacol. 1, 191-201 (1990).
63. Magistretti, P.J. and Pellerin, L. Astrocytes Couple Synaptic Activity to Glucose Utilization in the Brain. News Physiol. Sci. 14, 177-182 (1999).
64. Reivich, M., Kuhl, D., Wolf, A., Greenberg, J., Phelps, M., Ido, T., Casella, V., Fowler, J., Hoffman, E., Alavi, A., Som, P., and Sokoloff, L. The [18F] fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ. Res. 44, 127-137 (1979).
65. Myers, R. and Hume, S. Small animal PET. Eur Neuropsychopharmacol. 12, 545-555 (2002).
66. Gambhir, S.S., Czernin, J., Schwimmer, J., Silverman, D.H., Coleman, R.E., and Phelps, M.E. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42, 1S-93S (2001).
67. Jagust, W.J. and Eberling, J.L. MRI, CT, SPECT, PET: their use in diagnosing dementia. Geriatrics 46, 28-35 (1991).
68. Coleman, P., Federoff, H. and Kurlan, R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155-1162 (2004).
69. Norfray, J.F. and Provenzale, J.M. Alzheimer's disease: neuropathologic findings and recent advances in imaging. AJR Am. J. Roentgenol. 182, 3-13 (2004).
70. Santens, P., De Bleecker, J., Goethals, P., Strijckmans, K., Lemahieu, I., Slegers, G., Dierckx, R., and De Reuck, J. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur. Neurol. 45, 19-27 (2001).
71. Hoffman, J.M., Welsh-Bohmer, K.A., Hanson, M., Crain, B., Hulette, C., Earl, N., and Coleman, R.E. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med. 41, 1920-1928 (2000).
72. Small, G.W., Ercoli, L.M., Silverman, D.H. et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 6037-6042 (2000).
73. Silverman, D.H., Small, G.W., Chang, C.Y. et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. J. Am. Med. Assoc. 286, 2120-2127 (2001).
74. Miller, G. Alzheimer's biomarker initiative hits its stride. Science 326, 386-389 (2009).
75. Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C., and Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343-349 (2007).
76. Nordberg, A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging 35 Suppl 1, S46-50 (2008).
77. Teipel, S.J., Drzezga, A., Bartenstein, P., Moller, H.J., Schwaiger, M., and Hampel, H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind crossover trial. Psychopharmacology (Berl). 187, 86-94 (2006).
78. Palop, J.J., Chin, J., Roberson, E.D. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711 (2007).
79. Kuntner, C., Kesner, A.L., Bauer, M. et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 11, 236-240 (2009).
80. Morgan, D. and Gordon, M.N. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behav. Neurosci. 122, 730-732 (2008).
81. Newhouse, P.A., Potter, A., Kelton, M., and Corwin, J. Nicotinic treatment of Alzheimer's disease. Biol. Psychiatry 49, 268-278 (2001).
82. Brooks, D.J. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2, 226-236 (2005).
83. O'Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., McKeith, I.G., and Williams, E.D. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol. Neurosurg. Psychiatry 78, 356-362 (2007).
84. Staley, J.K., Krishnan-Sarin, S., Cosgrove, K.P. et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J. Neurosci. 26, 8707-8714 (2006).
85. Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., and Seibyl, J. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57, 2089-2094 (2001).
86. Warwick, J.M. Imaging of brain function using SPECT. Metab. Brain Dis. 19, 113-123 (2004).
87. Matsuda, H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J. Nucl. Med. 48, 1289-1300 (2007).
88. Small, G.W., Bookheimer, S.Y., Thompson, P.M., Cole, G.M., Huang, S.C., Kepe, V., and Barrio, J.R. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7, 161-172 (2008).
89. Borroni, B., Anchisi, D., Paghera, B. et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol. Aging. 27, 24-31 (2006).
90. Franc, B.L., Acton, P.D., Mari, C., and Hasegawa, B.H. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J. Nucl. Med. 49, 1651-1663 (2008).
91. Kim, K.M., Watabe, H., Hayashi, T. et al. Quantitative mapping of basal and vasareactive cerebral blood flow using split-dose 123I-iodoamphetamine and single photon emission computed tomography. Neuroimage 33, 1126-1135 (2006).